115 related articles for article (PubMed ID: 15084702)
21. [Gene therapy for primary immunodeficiency diseases].
Ariga T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():641-5. PubMed ID: 16416867
[No Abstract] [Full Text] [Related]
22. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
23. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
24. [Hematopoietic malignancies and gene therapy].
Ozawa K
Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
[TBL] [Abstract][Full Text] [Related]
25. A tragic setback.
Check E
Nature; 2002 Nov; 420(6912):116-8. PubMed ID: 12432357
[No Abstract] [Full Text] [Related]
26. Gene therapists hopeful as trials resume with childhood disease.
Check E
Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
[No Abstract] [Full Text] [Related]
27. Clinical research. Gene therapy a suspect in leukemia-like disease.
Marshall E
Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
[No Abstract] [Full Text] [Related]
28. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
29. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
30. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
31. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
32. US panel advises resumption of gene trials.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1068-9. PubMed ID: 12410240
[No Abstract] [Full Text] [Related]
33. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
34. Success and setback: another adverse event.
Verma IM
Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
[No Abstract] [Full Text] [Related]
35. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; PĂ©rez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
36. SCID trials to remain on the 'bubble'.
Mandavilli A
Nat Med; 2003 Mar; 9(3):251. PubMed ID: 12612562
[No Abstract] [Full Text] [Related]
37. [The current status of gene therapy in severe immunodeficiency].
Winckler T
Pharm Unserer Zeit; 2009; 38(3):204-6. PubMed ID: 19396911
[No Abstract] [Full Text] [Related]
38. Insertional oncogenesis in gene therapy: how much of a risk?
Sadelain M
Gene Ther; 2004 Apr; 11(7):569-73. PubMed ID: 15029226
[No Abstract] [Full Text] [Related]
39. [Setback for gene therapy: Two cases of leukemia in a French trial].
Richter J; Relander T; Fasth A; Karlsson S
Lakartidningen; 2003 Feb; 100(7):498-500. PubMed ID: 12640983
[No Abstract] [Full Text] [Related]
40. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]